MétaCan
Menu
Back to cohort
Record W7132915683

The Utility of Second-Tier Genomic Sequencing for Hereditary Cancer Syndromes: A Mixed-Methods Study

2023· dissertation· W7132915683 on OpenAlexaboutno aff
Salma Ali Shickh

Bibliographic record

VenueTSpace · 2023
Typedissertation
Language
FieldBiochemistry, Genetics and Molecular Biology
TopicBRCA gene mutations in cancer
Canadian institutionsnot available
Fundersnot available
KeywordsPenetranceCancerIdentification (biology)Genetic testingQualitative researchDiseaseCancer screening
DOInot available

Abstract

fetched live from OpenAlex

Background: Identification of patients with hereditary cancer syndromes (HCS) is important to detect high-risk patients who become eligible for surveillance and preventive surgeries that reduce cancer risk or detect it earlier, reducing morbidity and mortality. Standard panels only identify 10-20% of HCS patients. Genomic sequencing (GS) may identify more high-risk patients; however, evidence demonstrating utility of GS in HCS is lacking. Methods: This mixed-methods thesis aimed to explore the utility of second-tier GS for HCS. The first study explored clinician-reported utility of GS for HCS and other indications through a qualitative study using semi-structured interviews with Canadian clinicians with GS experience. Transcripts were thematically analyzed using constant comparison. The second study evaluated clinical utility of second-tier GS for HCS through chart review and survey conducted for cancer patients undergoing GS in an RCT. Charts were reviewed to extract diagnostic yield and management changes data. The final study explored patient-reported utility of cancer GS results by conducting a qualitative study using semi-structured interviews with patients who received second-tier GS as part of the aforementioned RCT. Transcripts were analyzed using constant comparison, similar to aim 1. Finally, a narrative approach was used to integrate quantitative and qualitative data. Results: All three studies suggest that GS provides limited utility above standard panels in HCS patients. The first qualitative study found that cancer clinicians attributed minimal utility from second-tier GS, who emphasized that the additional low/moderate penetrance results identified would not change management. The second study revealed that second-tier GS identified pathogenic results in 10% of patients, most in low/moderate penetrance genes with minimal actionability and at the cost of a high VUS rate of 90%. Findings from the third study indicated that patients centered their perceptions of utility of GS results on whether they changed management. Consequently, patients without management changes perceived anxiety and became hypervigilant, experiencing harms. Conclusions: As a second-tier test, GS provided limited utility for cancer patients and may be triggering harms. Our findings call for practice interventions to support patients receiving uninformative results from cancer genetic testing and for research to establish the utility of first-tier GS in HCS.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.099
metaresearch head score (Gemma)0.123
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Qualitative · Consensus signal: Qualitative
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.099
Threshold uncertainty score0.523

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0990.123
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0010.003
Bibliometrics0.0040.003
Science and technology studies0.0020.002
Scholarly communication0.0040.003
Open science0.0020.004
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0030.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.043
GPT teacher head0.422
Teacher spread0.379 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designQualitative
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2023
Admission routes1
Has abstractyes

Explore more

Same venueTSpaceSame topicBRCA gene mutations in cancerFrench-language works237,207